Compared to other tumor targets that are vastly used in nuclear medicine such as prostate-specific membrane antigen (PSMA) or somatostatin receptor (SSTR), radiopharmaceuticals targeting FAP do not address the cancer cells directly but indirectly via its TME. Here, FOLH1 is linked to cancer.